Sanofi Genzyme deserts gene therapy developer Voyager Therapeutics
While gene therapy companies rejoice as the sector gains traction with approvals and a flurry of M&A activity, one player is feeling the heat.
Back in 2015, Voyager Therapeutics joined forces with Sanofi Genzyme in a deal worth up to $845 million ($100 million upfront + a potential $745 million in milestones) to co-develop gene therapies for severe central nervous system disorders. But two years later, the French drugmaker retreated, electing to not pick up the option to work on Voyager’s Parkinson’s disease program. (Last year, the FDA disappointed Voyager, telling the company that it was not open to an accelerated filing on the Parkinson’s drug on the basis of Phase II data — instead requiring an additional pivotal study.)
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.